Pictor Limited Announces Start of US Clinical Trials for SARS-CoV-2 Serology Test

Wednesday 27th October 2021

Auckland-based diagnostic biotech company Pictor has taken a major step forward in the development of its COVID-19 antibody test, announcing it has signed two US laboratories to conduct clinical trials in the US.

Earlier this year, Pictor announced it had achieved a breakthrough with its COVID-19 IgG antibody test which identifies individuals with antibodies arising from infection with SARS-CoV-2 or as a result of vaccination.

THE US trials will be used to support a regulatory submission to the US Food & Drug Administration (FDA) under the Emergency Use Authorization for market clearance of the company’s SARS-CoV-2 serology test.

Boca Biolistics of Pompano Beach, Florida and Rain Incubator of Tacoma, Washington have entered into clinical testing agreements for the evaluation of Pictor’s serology test.

The Pictor serology test detects simultaneously antibodies to two major viral antigens – the spike protein and nucleocapsid protein. Antibodies to the nucleocapsid proteins can be used to confirm previous infection in individuals, while detection of antibodies to the spike antigen can be used to identify individuals vaccinated with anti-spike antigen vaccines.

The test was developed was developed in Pictor’s Auckland lab with funding from the New Zealand Government’s COVID-19 Innovation Acceleration Fund, and is the subject of provisional patent submission to the USPTO.

“The Pictor SARS-CoV-2 serology assay is a low-cost, duplex, miniaturised test capable of simultaneous detection of the two antibodies resulting from infection or vaccination,” says Pictor Chief Technology Officer Dr Richard Janeczko.

“In Pictor’s recently concluded Alpha Trial the assay exhibited high clinical performance across samples from different individuals. We chose to work with Boca Bio and Rain Incubator because of their vast experience in COVID-19 testing and look forward to extending and demonstrating the uniqueness and versatility of our assay in the trials at both sites. The trials are expected to begin in late October and conclude in November.”

Pictor Chief Operating Officer Howard Moore says: “As COVID-19 remains a global concern, measuring antibody levels across different populations will be critical for public health initiatives to inform control of potential surges of emerging variants.”

Quote from Boca Biolistics

“With the expertise Boca Biolistics has developed from our involvement in global viral outbreaks, such as Zika and COVID-19, we look forward to contributing our know-how in infectious disease management, laboratory testing, and clinical trial services to Pictor Ltd,” says Valentin Adia, Chief Executive Officer, Boca Biolistics, LLC.

Quote from Rain Incubator

“This type of testing is essential to public health efforts,” says Dr David Hirschberg, Rain founder and neuroimmunologist. “Pictor assays have the potential to help us understand vaccine efficacy against emerging variants, as well as antibody longevity in vaccinated and post infection individuals. This information will guide public health recommendations on who should get vaccinated or boosted and when, which can help reduce the spread of COVID-19 and future disease targets. Technology that can be pivoted to newly emerging diseases is important, so that we can more rapidly and effectively address future outbreaks before they become pandemics.”

About Pictor

Pictor was founded in 2005 by scientists, Dr Anand Kumble and Dr Sarita Kumble, who retired in 2017. Pictor has since expanded and now has 33 employees in the United States, New Zealand, Europe and India. In August 2020 Pictor established Pictor Inc. in the United States and appointed Dr Thomas Schlumpberger as its new CEO, based in San Francisco. Howard Moore, the previous CEO, is now COO.

Pictor recently announced it has achieved a breakthrough with its COVID-19 IgG antibody test. The diagnostic test, developed on Pictor’s multiplex platform, can differentiate individuals who have antibodies arising from being infected from those who have been vaccinated.

For more information, and to request an interview please contact: Mark Russell – +64 27 297 0178 or mark@hotmetal.nz

Source: Pictor Limited

Comments from our readers

No comments yet